About NGFI-A-binding protein 1
NGFI-A-binding protein 1 (NAB1) is a protein
from Homo sapiens identified by UniProt accession
Q13506, 487 residues long.
MolForge cross-references it against 0 known binders and
70 disease associations.
Target properties
| Protein name | NGFI-A-binding protein 1 |
| UniProt accession | Q13506 |
| Gene | NAB1 |
| Organism | Homo sapiens |
| Length | 487 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (70)
Diseases linked to this target (Open Targets).
- sex hormone-binding globulin measurement · score 0.43
- primary biliary cirrhosis · score 0.41
- systolic blood pressure · score 0.41
- heel bone mineral density · score 0.38
- systemic scleroderma · score 0.38
- rheumatoid arthritis · score 0.37
- systemic lupus erythematosus · score 0.36
- autoimmune disease · score 0.30
- biliary liver cirrhosis · score 0.30
- myositis · score 0.30
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13506-F1 | alphafold | PREDICTED | 64.40 | — |
Amino-acid sequence (487 residues)
MAAALPRTLG ELQLYRILQK ANLLSYFDAF IQQGGDDVQQ LCEAGEEEFL EIMALVGMAS KPLHVRRLQK ALRDWVTNPG LFNQPLTSLP VSSIPIYKLP EGSPTWLGIS CSSYERSSNA REPHLKIPKC AATTCVQSLG QGKSDVVGSL ALQSVGESRL WQGHHATESE HSLSPADLGS PASPKESSEA LDAAAALSVA ECVERMAPTL PKSDLNEVKE LLKTNKKLAK MIGHIFEMND DDPHKEEEIR KYSAIYGRFD SKRKDGKHLT LHELTVNEAA AQLCVKDNAL LTRRDELFAL ARQISREVTY KYTYRTTKSK CGERDELSPK RIKVEDGFPD FQDSVQTLFQ QARAKSEELA ALSSQQPEKV MAKQMEFLCN QAGYERLQHA ERRLSAGLYR QSSEEHSPNG LTSDNSDGQG ERPLNLRMPN LQNRQPHHFV VDGELSRLYP SEAKSHSSES LGILKDYPHS AFTLEKKVIK TEPEDSR
Explore NGFI-A-binding protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets